| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000031207 |
| Receipt No. | R000035185 |
| Scientific Title | Effect of Enzymolyzed Honeybee Larvae on tinnitus-related symptoms. |
| Date of disclosure of the study information | 2019/02/20 |
| Last modified on | 2022/05/19 (Ver. 3) |
| Basic information | ||
| Public title | Effect of Enzymolyzed Honeybee Larvae on tinnitus-related symptoms. | |
| Acronym | Effect of Enzymolyzed Honeybee Larvae on tinnitus-related symptoms. | |
| Scientific Title | Effect of Enzymolyzed Honeybee Larvae on tinnitus-related symptoms. | |
| Scientific Title:Acronym | Effect of Enzymolyzed Honeybee Larvae on tinnitus-related symptoms. | |
| Region |
|
|
| Condition | ||
| Condition | Adult | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy and safety of Enzymolyzed Honeybee Larvae on mild tinnitus-related symptoms. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1. Visual Analog Scale(VAS) score
(laudness, time, annoyance and total score of them). |
| Key secondary outcomes | 1. Tinnitus Handicap Inventory(THI)
2. VAS score (hearing, dizziness, fatigue, awakening and asleep). 3. Adverse events, physiological examination, hematological examination, blood biochemical examination, and urinalysis before intake and 4week. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 4 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Enzymolyzed Honeybee Larvae product 1
Ingestion 720 mg per day Period 4 week |
|
| Interventions/Control_2 | Enzymolyzed Honeybee Larvae product 2
Ingestion 360 mg per day Period 4 week |
|
| Interventions/Control_3 | Enzymolyzed Honeybee Larvae product 3
Ingestion 180 mg per day Period 4 week |
|
| Interventions/Control_4 | Placebo product
Period 4 week |
|
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Target subjects must satisfy the following selection criteria.
1. Healthy Japanese with tinnitus aged between 40 and 75 years old 2. Not received medical treatment, therapy or treatment, regardless of seasonality, chronic or sudden diseases 3. with written consent spontaneously 4. Can prohabit excessive exercise 5. Can prohabit drinking and eating too much 6. Can prevent conception 7. Can understand and comply with the rules written in protocol 8. Judged appropriate for participation in this study by the doctor. |
|||
| Key exclusion criteria | The subjects in conflict with any of the following condition are excluded.
1. Have ingested bee larvea-containing food in 2018 2. No consciousness of tinnitus 3. With a THI score =0 or >=38 4. Under treatment for tinnitus 5. Have a disorder affecting the examination, such as otolaryngology system, internal medicine system (diabetes, cardiovascular disease) 6. With food allergies 7. Ingest medicines or health foods that may affect test results 8. Have restriction of niacin from doctor 9. Pregnant or breast-feeding women, or applicant of pregnancy 10. With a disease in the gastrointestinal tract, liver, kidney, heart and cardiovascular affecting absorption, distribution, metabolism, excretion of the test food 11. Have a history of cerebrovascular disorder, cranial nerve disease, etc. 12. Underwent blood sampling (=<200 mL within 4 weeks, or =<400 mL within 3 months) before the start of this study. 13. Be Suspected alcohol or drug dependence 14. Had participated over the past 3 months, or currently participate in other clinical trials 15. Have a irregular habit 16. Have a housemate participating or scheduling to participate this clinical study. 17. Cannot comply with the rules written in protocol 18. Judged inappropriate for participation in this study by the doctor. |
|||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Medical corporation Koganeibasi Sakura Clinic | ||||||
| Division name | Not applicable | ||||||
| Zip code | |||||||
| Address | 2-11-25 Sakuramachi, Koganei-city, Tokyo, 184-0005, Japan | ||||||
| TEL | 042-382-5252 | ||||||
| info@kb-clinic.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Yamada Bee Company, Inc. | ||||||
| Division name | Institute for Bee Products & Health Science | ||||||
| Zip code | |||||||
| Address | 194 Ichiba, Kagamino-cho, Tomata-gun, Okayama 708-0393 Japan | ||||||
| TEL | 0868-54-1199 | ||||||
| Homepage URL | |||||||
| hn1726@yamada-bee.com | |||||||
| Sponsor | |
| Institute | Yamada Bee Company, Inc.
|
| Institute | |
| Department | |
| Funding Source | |
| Organization | Yamada Bee Company, Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Research Center for Immunological Analysis. Inc. |
| Name of secondary funder(s) | none |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035185 |